A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusion

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Chiazza, Fausto ^a   Chegaev, Konstantin ^a   Rogazzo, Mara ^a   Cutrin, Juan C ^a,b   Benetti, Elisa ^a   Lazzarato, Loretta ^a   Fruttero, Roberta ^a   Collino, Massimo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; FREE RADICALS; IMMUNOLOGY; UREA;

FREE RADICAL SCAVENGERS; ISCHEMIA/REPERFUSION; ISCHEMIC INJURIES; LIPID PEROXIDATION; NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN; NITRIC OXIDE DONOR; PROTECTIVE EFFECTS; RENAL DYSFUNCTION;

NITRIC OXIDE;

4 [[4 (3 METHYL 5 OXO 4,5 DIHYDRO 1H PYRAZOL 1 YL)PHENOXY]METHYL]FUROXAN 3 CARBOXAMIDE; AMIDE; ANTIOXIDANT; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MALONALDEHYDE; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NORPHENAZONE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA; ACUTE PHASE PROTEIN; FUROXANS; LIPOCALIN; N ACETYLGLUCOSAMINE; NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN PROTEIN, RAT; NITRIC OXIDE DONOR; ONCOPROTEIN; OXADIAZOLE DERIVATIVE; PHENAZONE; PHENYLMETHYLPYRAZOLONE; SCAVENGER;

ACUTE DRUG ADMINISTRATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLOMERULAR DYSFUNCTION; HISTOPATHOLOGY; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REPERFUSION INJURY; TUBULAR DYSFUNCTION; UPREGULATION; UREA BLOOD LEVEL; URINE FLOW RATE; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; ISCHEMIA; KIDNEY; METABOLISM; PATHOLOGY; URINE; WISTAR RAT;

RATTUS NORVEGICUS;

ACETYLGLUCOSAMINE; ACUTE-PHASE PROTEINS; ANIMALS; ANTIPYRINE; CREATININE; DISEASE MODELS, ANIMAL; FREE RADICAL SCAVENGERS; ISCHEMIA; KIDNEY; LIPID PEROXIDATION; LIPOCALINS; MALE; MALONDIALDEHYDE; NITRIC OXIDE DONORS; OXADIAZOLES; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; REPERFUSION INJURY; UREA;

EID: 84925340761     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/804659     Document Type: Article

References (61)

1. A. Pérez-González and A. Galano, "OH radical scavenging activity of edaravone: mechanism and kinetics," Journal of Physical Chemistry B, vol. 115, no. 5, pp. 1306-1314, 2011.
2. K. Toyoda, K. Fujii, M. Kamouchi et al., "Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion," Journal of the Neurological Sciences, vol. 221, no. 1-2, pp. 11-17, 2004.
3. K. Tsujita, H. Shimomura, H. Kawano et al., "Effects of edaravone on reperfusion injury in patients with acute myocardial infarction," The American Journal of Cardiology, vol. 94, no. 4, pp. 481-484, 2004.
4. T. Watanabe, M. Tahara, and S. Todo, "The novel antioxidant edaravone: from bench to bedside," Cardiovascular Therapeutics, vol. 26, no. 2, pp. 101-114, 2008.
5. M. Kamouchi, H. Sakai, Y. Kiyohara, K. Minematsu, K. Hayashi, and T. Kitazono, "Acute kidney injury and edaravone in acute ischemic stroke: the fukuoka stroke registry," Journal of Stroke and Cerebrovascular Diseases, vol. 22, no. 8, pp. e470-e476, 2013.
6. M. Tahara, M. Nakayama, M. B. Jin et al., "A radical scavenger, edaravone, protects canine kidneys from ischemia-reperfusion injury after 72 hours of cold preservation and autotransplantation," Transplantation, vol. 80, no. 2, pp. 213-221, 2005.
7. M. Matsuyama, T. Hayama, K. Funao et al., "Treatment with edaravone improves the survival rate in renal warm ischemiareperfusion injury using rat model," Transplantation Proceedings, vol. 38, no. 7, pp. 2199-2200, 2006.
8. K. Sueishi, K. Mishima, K. Makino et al., "Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats," European Journal of Pharmacology, vol. 451, no. 2, pp. 203-208, 2002.
9. T. Iguchi, M. Nishikawa, B. Chang et al., "Edaravone inhibits acute renal injury and cyst formation in cisplatin-treated rat kidney," Free Radical Research, vol. 38, no. 4, pp. 333-341, 2004.
10. R. Bellomo, J. A. Kellum, and C. Ronco, "Acute kidney injury," The Lancet, vol. 380, no. 9843, pp. 756-766, 2012.
11. P. N. A. Martins, A. Chandraker, and S. G. Tullius, "Modifying graft immunogenicity and immune response prior to transplantation: potential clinical applications of donor and graft treatment," Transplant International, vol. 19, no. 5, pp. 351-359, 2006.
12. D. S. A. Majid and L. G. Navar, "Nitric oxide in the control of renal hemodynamics and excretory function," The American Journal of Hypertension, vol. 14, no. 6, pp. 74S-82S, 2001.
13. E. L. Rhoden, C. R. Rhoden, M. L. Lucas, L. Pereira-Lima, C. Zettler, and A. Belló-Klein, "The role of nitric oxide pathway in the renal ischemia-reperfusion injury in rats," Transplant Immunology, vol. 10, no. 4, pp. 277-284, 2002.
14. K. Chegaev, L. Lazzarato, B. Rolando et al., "NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization," Journal of Pineal Research, vol. 42, no. 4, pp. 371-385, 2007.
15. C. Cena, K. Chegaev, S. Balbo et al., "Novel antioxidant agents deriving from molecular combination of vitamin C and NOdonor moieties," Bioorganic and Medicinal Chemistry, vol. 16, no. 9, pp. 5199-5206, 2008.
16. K. Chegaev, C. Cena, M. Giorgis et al., "Edaravone derivatives containing NO-donor functions," Journal of Medicinal Chemistry, vol. 52, no. 2, pp. 574-578, 2009.
17. M. Collino, E. Benetti, G. Miglio et al., "Peroxisome proliferator-activated receptor β/δ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats," Free Radical Biology and Medicine, vol. 50, no. 2, pp. 345-353, 2011.
18. N. S. A. Patel, S. Cuzzocrea, M. Collino et al., "The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo," European Journal of Pharmacology, vol. 562, no. 1-2, pp. 148-154, 2007.
19. M. Collino, M. Rogazzo, A. Pini et al., "Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury," Journal of Cellular and Molecular Medicine, vol. 17, no. 11, pp. 1494-1505, 2013.
20. K. Doi, Y. Suzuki, A. Nakao, T. Fujita, and E. Noiri, "Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney," Kidney International, vol. 65, no. 5, pp. 1714-1723, 2004.
21. Y. Li, A.-Z. Xia, and S.-H. Xing, "Protective effect of edaravone against renal ischemia/reperfusion injury and compared with ischemic postconditioning in rats," Yaoxue Xuebao, vol. 45, no. 7, pp. 840-848, 2010.
22. C. Bazzi, C. Petrini, V. Rizza et al., "Urinary N-acetyl-β- glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis," Nephrology Dialysis Transplantation, vol. 17, no. 11, pp. 1890-1896, 2002.
23. J. Mishra, M. A. Qing, A. Prada et al., "Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury," Journal of the American Society of Nephrology, vol. 14, no. 10, pp. 2534-2543, 2003.
24. N. S. A. Patel, H. L. Kerr-Peterson, M. Brines et al., "Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury," Molecular Medicine, vol. 18, pp. 719-727, 2012.
25. M. Kenan Kinaci, N. Erkasap, A. Kucuk, T. Koken, and M. Tosun, "Effects of quercetin on apoptosis, NF-kappaB and NOS gene expression in renal ischemia/reperfusion injury," Experimental and Therapeutic Medicine, vol. 3, no. 2, pp. 249-254, 2012.
26. N. Zhang, M. Komine-Kobayashi, R. Tanaka, M. Liu, Y. Mizuno, and T. Urabe, "Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain," Stroke, vol. 36, no. 10, pp. 2220-2225, 2005.
27. Y. Higashi, D. Jitsuiki, K. Chayama, and M. Yoshizumi, "Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases," Recent Patents on Cardiovascular Drug Discovery, vol. 1, no. 1, pp. 85-93, 2006.
28. M. Tamamura, M. Saito, Y. Kinoshita et al., "Protective effect of edaravone, a free-radical scavenger, on ischaemia-reperfusion injury in the rat testis," BJU International, vol. 105, no. 6, pp. 870-876, 2010.
29. M. Shimoda, Y. Iwasaki, T. Okada, and K. Kubota, "Edaravone inhibits apoptosis caused by ischemia/reperfusion injury in a porcine hepatectomy model," World Journal of Gastroenterology, vol. 18, no. 27, pp. 3520-3526, 2012.
30. M. Kara, Y. K. Daglioglu, Y. Kuyucu, A. Tuli, and O. Tap, "The effect of edaravone on ischemia-reperfusion injury in rat ovary," European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 162, no. 2, pp. 197-202, 2012.
31. A. Urbschat, K. Zacharowski, N. Obermüller et al., "The small fibrinopeptide Bβ15-42 as renoprotective agent preserving the endothelial and vascular integrity in early ischemia reperfusion injury in the mouse kidney," PLoS ONE, vol. 9, no. 1, Article ID e84432, 2014.
32. M. A. Bellinger, J. S. Bean, M. A. Rader et al., "Concordant changes of plasma and kidney microRNA in the early stages of acute kidney injury: time course in a mouse model of bilateral renal ischemia-reperfusion," PLoS ONE, vol. 9, no. 4, Article ID e93297, 2014.
33. R. di Paola, D. Impellizzeri, P. Mondello et al., "Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice," Shock, vol. 38, no. 4, pp. 356-366, 2012.
34. C. L. Edelstein, H. Ling, and R.W. Schrier, "The nature of renal cell injury," Kidney International, vol. 51, no. 5, pp. 1341-1351, 1997.
35. B. R. Clapp, A. D. Hingorani, R. K. Kharbanda et al., "Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress," Cardiovascular Research, vol. 64, no. 1, pp. 172-178, 2004.
36. H. Ogita and J. K. Liao, "Endothelial function and oxidative stress," Endothelium, vol. 11, no. 2, pp. 123-132, 2004.
37. C. Caramelo, G. Espinosa, F. Manzarbeitia et al., "Role of endothelium-related mechanisms in the pathophysiology of renal ischemia/reperfusion in normal rabbits," Circulation Research, vol. 79, no. 5, pp. 1031-1038, 1996.
38. D. Schwartz, M. Mendonca, I. Schwartz et al., "Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats," The Journal of Clinical Investigation, vol. 100, no. 2, pp. 439-448, 1997.
39. L. Schramm, E. Heidbreder, A. Schmitt et al., "Role of Larginine-derived NO in ischemic acute renal failure in the rat," Renal Failure, vol. 16, no. 5, pp. 555-569, 1994.
40. S. Linas, D. Whittenburg, and J. E. Repine, "Nitric oxide prevents neutrophil-mediated acute renal failure," The American Journal of Physiology-Renal Physiology, vol. 272, no. 1, pp. F48-F54, 1997.
41. P. Tripatara, N. S. A. Patel, A. Webb et al., "Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase," Journal of the American Society of Nephrology, vol. 18, no. 2, pp. 570-580, 2007.
42. L. C. Cantley, "The phosphoinositide 3-kinase pathway," Science, vol. 296, no. 5573, pp. 1655-1657, 2002.
43. E. A. El Eter and A. Aldrees, "Inhibition of proinflammatory cytokines by SCH79797, a selective protease-activated receptor 1 antagonist, protects rat kidney against ischemia-reperfusion injury," Shock, vol. 37, no. 6, pp. 639-644, 2012.
44. H.-S. Jang, J. Kim, K. Y. Kim, J. I. Kim, M. H. Cho, and K. M. Park, "Previous ischemia and reperfusion injury results in resistance of the kidney against subsequent ischemia and reperfusion insult in mice; A role for the Akt signal pathway," Nephrology Dialysis Transplantation, vol. 27, no. 10, pp. 3762-3770, 2012.
45. D. E. Choi, J. Y. Jeong, B. J. Limet al., "Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats," Renal Physiology-American Journal of Physiology, vol. 297, pp. F362-F370, 2009.
46. A. Satake, M. Takaoka, M. Nishikawa et al., "Protective effect of 17β-estradiol on ischemic acute renal failure through the PI3K/Akt/eNOS pathway," Kidney International, vol. 73, no. 3, pp. 308-317, 2008.
47. X. Liu, H. Chen, B. Zhan et al., "Attenuation of reperfusion injury by renal ischemic postconditioning: the role of NO," Biochemical and Biophysical Research Communications, vol. 359, no. 3, pp. 628-634, 2007.
48. A.-A. M. Hussein, N. Barakat, A. Awadalla, and A. A. Shokeir, "Systemic and renal haemodynamic changes in renal schemia/reperfusion injury: impact of erythropoietin," Canadian Journal of Physiology and Pharmacology, vol. 90, no. 11, pp. 1535-1543, 2012.
49. P. K. Chatterjee, N. S. A. Patel, E. O. Kvale et al., "Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury," Kidney International, vol. 61, no. 3, pp. 862-871, 2002.
50. K. K. Donnahoo, B. D. Shames, A. H. Harken, and D. R. Meldrum, "The role of tumor necrosis factor in renal ischemiareperfusion injury," The Journal of Urology, vol. 162, no. 1, pp. 196-203, 1999.
51. L. M. Walker, P. D. Walker, S. Z. Imam, S. F. Ali, and P. R. Mayeux, "Evidence for peroxynitrite formation in renal ischemia-reperfusion injury: studies with the inducible nitric oxide synthase inhibitor L-N6-(1-iminoethyl)lysine," Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 1, pp. 417-422, 2000.
52. K. M. Park, J.-Y. Byun, C. Kramers, J. I. Kim, P. L. Huang, and J. V. Bonventre, "Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney," The Journal of Biological Chemistry, vol. 278, no. 29, pp. 27256-27266, 2003.
53. J. Torras, I. Herrero-Fresneda, N. Lloberas, M. Riera, J. M. Cruzaoo, and J. M. Grinyo, "Promising effects of ischemic preconditioning in renal transplantation," Kidney International, vol. 61, no. 6, pp. 2218-2227, 2002.
54. J. I. Kim, H.-S. Jang, and K. M. Park, "Endotoxin-induced renal tolerance against ischemia and reperfusion injury is removed by iNOS, but not eNOS, gene-deletion," BMB Reports, vol. 43, no. 9, pp. 629-634, 2010.
55. M. S. Goligorsky, S. V. Brodsky, and E. Noiri, "Nitric oxide in acute renal failure: NOS versus NOS," Kidney International, vol. 61, no. 3, pp. 855-861, 2002.
56. M. S. Paller, J. R. Hoidal, and T. F. Ferris, "Oxygen free radicals in ischemic acute renal failure in the rat," The Journal of Clinical Investigation, vol. 74, no. 4, pp. 1156-1164, 1984.
57. H.-B. Peng, P. Libby, and J. K. Liao, "Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NFkappa B," The Journal of Biological Chemistry, vol. 270, no. 23, pp. 14214-14219, 1995.
58. J.R. Matthews, C. H. Botting, M. Panico, H.R. Morris, and R. T. Hay, "Inhibition of NF-κBDNAbinding by nitric oxide," Nucleic Acids Research, vol. 24, no. 12, pp. 2236-2242, 1996.
59. G. Dijkstra, H. Moshage, and P. L. M. Jansen, "Blockade of NF-κB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease?" Scandinavian Journal of Gastroenterology, Supplement, vol. 37, no. 236, pp. 37-41, 2002.
60. J. V. Bonventre and A. Zuk, "Ischemic acute renal failure: an inflammatory disease?" Kidney International, vol. 66, no. 2, pp. 480-485, 2004.
61. K. Furuichi, S. Kaneko, and T. Wada, "Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease," Clinical and Experimental Nephrology, vol. 13, no. 1, pp. 9-14, 2009.